CRYSTAL DEPOSITION DISEASES: Edited by Ann K. RosenthalCurrent advances in therapies for calcium pyrophosphate crystal arthritisSivera, Francisca; Andrés, Mariano; Pascual, EliseoAuthor Information aSección de Reumatología, Hospital General Universitario de Elda bSección de Reumatología, Hospital General Universitario de Alicante cDepartamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain *Francisca Sivera and Mariano Andrés equally contributed to the writing of this manuscript and share first authorship. Correspondence to Eliseo Pascual, Sección Reumatología, Hospital General Universitario de Alicante, c/ Pintor Baeza 12, 03010, Alicante, Spain. Tel: +34 965933015; fax: +34 965913786; e-mail: email@example.com Current Opinion in Rheumatology: March 2016 - Volume 28 - Issue 2 - p 140-144 doi: 10.1097/BOR.0000000000000252 Buy Metrics Abstract Purpose of review Calcium pyrophosphate (CPP) crystal disease is a common rheumatologic disorder that has received limited attention from the scientific community. This review is aimed at summarizing current evidence for managing CPP disease (CPPD), focusing on recently reported advances. Recent findings New data from case series indicate that interleukin-1β inhibitors can help patients with refractory forms of CPPD. Methotrexate, formerly a promising agent, failed to demonstrate benefits in a recent trial, but still merits consideration for some patients. No significant advances on crystal dissolution have been achieved to date. Proper characterization of the CPP crystal disease picture is needed, ruling out the possible coexistence of another persistent arthritis unrelated to the CPP deposition. Summary Advances on CPP crystal dissolution and establishing definitions of the clinical spectrum of CPPD remain the main challenges for CPP crystal disease management. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.